KLAR — Klaria Pharma Holding AB (publ) Share Price
Last trade - 00:00- SEK46.86m
- SEK45.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.45 | ||
| Price to Tang. Book | 1.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | -68.65 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.81% | ||
| Return on Equity | -29.41% | ||
| Operating Margin | 1265.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 4.22 | n/a | n/a | 5.87 | n/a | 89 | 28 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Klaria Pharma Holding AB (publ) is a Sweden-based holding company engaged in the biotechnology and medical research industry. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The Company operates Klaria Pharma AB as a wholly owned subsidiary.
Directors
- Bjorn Littorin CHM (74)
- Jesper Wiklund CEO
- Hans Richter CFO (72)
- Leif Ingemarsson CTO (56)
- Scott Boyer CSO (57)
- Kristina Liden Mascher OTH (56)
- Michael Brobjer DRC (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 22nd, 2014
- Public Since
- October 21st, 2015
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 106,500,523
- Address
- Virdings Alle 2, UPPSALA, 754 50
- Web
- https://www.klaria.com/
- Phone
- +46 84464299
- Contact
- Scott Boyer
- Auditors
- BDO Malardalen AB
Upcoming Events for KLAR
Similar to KLAR
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 21:39 UTC, shares in Klaria Pharma Holding AB (publ) are trading at SEK0.40. This share price information is delayed by 15 minutes.
Shares in Klaria Pharma Holding AB (publ) last closed at SEK0.40 and the price had moved by -19.56% over the past 365 days. In terms of relative price strength the Klaria Pharma Holding AB (publ) share price has underperformed the FTSE Global All Cap Index by -29.26% over the past year.
There is no consensus recommendation for this security.
Klaria Pharma Holding AB (publ) does not currently pay a dividend.
Klaria Pharma Holding AB (publ) does not currently pay a dividend.
Klaria Pharma Holding AB (publ) does not currently pay a dividend.
To buy shares in Klaria Pharma Holding AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.40, shares in Klaria Pharma Holding AB (publ) had a market capitalisation of SEK42.49m.
Here are the trading details for Klaria Pharma Holding AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: KLAR
Based on an overall assessment of its quality, value and momentum Klaria Pharma Holding AB (publ) is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Klaria Pharma Holding AB (publ) is SEK1.00. That is 150.63% above the last closing price of SEK0.40.
Analysts covering Klaria Pharma Holding AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of SEK0.10 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Klaria Pharma Holding AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -26.33%.
As of the last closing price of SEK0.40, shares in Klaria Pharma Holding AB (publ) were trading -11.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Klaria Pharma Holding AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Klaria Pharma Holding AB (publ)'s management team is headed by:
- Bjorn Littorin - CHM
- Jesper Wiklund - CEO
- Hans Richter - CFO
- Leif Ingemarsson - CTO
- Scott Boyer - CSO
- Kristina Liden Mascher - OTH
- Michael Brobjer - DRC